Data science and AI continue to make healthcare headlines because of their potential to change everything from how drugs are developed to revolutionizing information workflows. One area where we ...

Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of ...

An Arlington woman has created a social impact company to provide confidence and healing to women who are battling cancer.

Colorectal cancer (CRC) is the second most common cause of death from cancer in the US and the most prevalent malignant tumor ...

In response to the growing interest in the use of AI technologies in clinical oncology, the number of AI start-ups that concentrate their efforts on combating cancer has surged. The present research ...

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, shares how one mobile health care initiative is addressing critical barriers to medical access for underserved populations.

Leading oncology research organization adopts Veeva Clinical Platform to enhance study delivery. PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and ...

A new at-home self-collection device is taking aim at the screening gap for cervical cancer, and new research, ... screen," says Christine Conageski, MD, ... Clinical Validation of a Vaginal ...

Clinical Cancer Research ; Molecular Cancer Research ; Molecular Cancer Therapeutics ... Department of Genetics, The University of Texas MD Anderson Cancer Center, Box 11, 1515 Holcombe Blvd., Houston ...

Colon cancer patients saw improved survival rates after a 3-year exercise program, according to a first-of-its-kind international experiment. The research, presented at the American Society of ...

“Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at ...

The cost of cancer care in the United States is estimated to exceed $245 in US dollars (USD) billion by 2030, largely because of the high cost of cancer drugs. 1 This has led prescribers and payers to ...